Events & Presentations

  • Jan. 11, 2023 Bioasis Technologies Inc. Mails Management Information Circular for Annual and Special Meeting of Securityholders

    NEW HAVEN, Conn., Jan. 11, 2023 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company…

  • Dec. 14, 2022 Bioasis Technologies Inc. Announces Shareholder Webinar

    NEW HAVEN, Conn., Dec. 14, 2022 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC. (TSXV:BTI) (OTCQB:BIOAF), (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company…

  • Mar. 8, 2021 Bioasis to Attend and Present at Upcoming Investor and Industry Conferences

    NEW HAVEN, Conn., March 08, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (TSXV:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical… Read more »

  • Jan. 4, 2021 Bioasis to Present at Upcoming Industry Conferences

    GUILFORD, Conn., Jan. 04, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. – Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high… Read more »

  • Jul. 10, 2020 Bioasis and Chiesi Group to Host Webcast on July 16, 2020

    GUILFORD, Conn., U.S.A. & PARMA, Italy–(Business Wire)– Bioasis Technologies, Inc. (“Bioasis”) (TSXV:BTI.V; OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including rare genetic diseases,… Read more »

  • Feb. 6, 2020 Bioasis to Present at the 22nd Annual BIO CEO Investor Conference and the OTC Markets 2020 Virtual Investor Conference

    GUILFORD, Conn.–(Business Wire)– Bioasis Technologies Inc. (OTCQB:BIOAF)(TSX.V:BTI), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that… Read more »

  • Jan. 6, 2020 Bioasis to Present at Upcoming Industry Conferences

    Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced… Read more »

  • Nov. 27, 2019 Bioasis to Host Annual General Meeting Webcast on December 5, 2019

    GUILFORD, Conn.–(Business Wire)–Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases,… Read more »

  • Dec. 13, 2018 Bioasis to Present at Investor & Industry Conferences in January 2019

    GUILFORD, Conn.–(Business Wire)–Bioasis Technologies Inc. (TSX.V:BTI)(OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that members of management will present at the following investor… Read more »

  • Nov. 20, 2018 Bioasis Announces Positive Results from Peripheral Whole-Body PET/CT Scan Study in Non-Human Primates with Lead Investigational Candidate xB3-001™

    xB 3 -001 demonstrated lymphatic system penetration and more selective tissue distribution with xB 3 -001 than trastuzumab alone The Company has filed patent applications based on these observations and those data may have broader applicability An updated version of the corporate presentation is available for review at www.bioasis.us/investors